ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer Post author:admERY Post published:June 27, 2011 Post category:Newsroom ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. You Might Also Like ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium January 17, 2017 ERYTECH to Host Second Quarter 2019 Conference Call and Business Update September 11, 2019 ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL April 4, 2017
ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL April 4, 2017